Efungumab: A novel agent in the treatment of invasive candidiasis

Annals of Pharmacotherapy

Volumn 43, Issue 11, 2009, Pages 1818-1823

  Karwa, Rakhi ^a   Wargo, Kurt A ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Efungumab; Heat shock protein 90; Invasive candidiasis; Mycograb

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFOTAXIME; EFUNGUMAB; FLUCONAZOLE; FLUCYTOSINE; GENTAMICIN; HEAT SHOCK PROTEIN 90; HYPERTENSIVE FACTOR; METRONIDAZOLE; MYCOGRAB; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; BIBLIOGRAPHIC DATABASE; BLOOD PRESSURE FLUCTUATION; CANDIDA; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; ENGLISH AS A SECOND LANGUAGE; FUNGAL VIABILITY; HUMAN; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; INVASIVE CANDIDIASIS; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; SIDE EFFECT; SYNDROME; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 70449717496     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M218     Document Type: Review

References (24)

1. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microbiol Infect Dis 2007; 26:377-384 DOI 10.1007/s10096-007-0316-2
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17. Erratum: Clin Infect Dis 2004;39:1093. Epub 15 Jul 2004.
3. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008;32(suppl 2):S87-91.
4. Cassone A. Fungal vaccines: real progress from real challenges. Lancet Infect Dis 2008;8:114-124
5. Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004;22:865-871 DOI 10.1016/j.vaccine.2003.11.032
6. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995;63:4211-4218
7. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 2005;51:19-29.
8. Matthews RC, Burnie JP. Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr Mol Med 2005;5:403-411
9. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005;309:2185-2189
10. Porsius JC, van Vliet HJ, van Zeijl JH, Goessens WH, Michel MF. Detection of an antibody response in immunocompetent patients with systemic candidiasis or Candida albicans colonisation. Eur J Clin Microbiol Infect Dis 1990;9:352-355
11. Cowen LE, Singh SD, Köhler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 2009;106:2818-2823 Epub 5 Feb 2009.
12. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003;47:2208-2216 DOI 10.1128/AAC.47.7.2208-2216. 2003 (Pubitemid 36753574)
13. Hodgetts S, Nooney L, Al-Akeel R, et al. Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother 2008;61: 1132-1139 Epub 25 Feb 2008. DOI 10.1093/jac/dkn075
14. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42:1404-1413 Epub 12 Apr 2006.
15. Rowlands HE, Morris K, Graham C. Human recombinant antibody against Candida. Pediatr Infect Dis J 2006;26:959-960
16. Sutherland A, Ellis D. Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole. Pediatr Crit Care Med 2008;9:e23-5. DOI 10.1097/PCC. 0b013e31817286e8
17. Spronk P, Van der Hoven B, Graham C, et al. Combination therapy with efungumab for the treatment of invasive Candida infections: several illustrative case reports (abstract P20). Crit Care 2008;12(suppl 2):P20. DOI 10.1186/cc6241
18. Herbrecht R, Fohrer C, Nivoix Y. Correspondence - Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006;43:1083-1084 (Pubitemid 44631113)
19. European Medicines Agency. Refusal CHMP assessment report for Mycograb. www.emea.europa.edu/humandocs/Humans/EPAR/mycograb/ mycograbR.htm (accessed 2009 Jun 9).
20. European Medicines Agency. Questions and answers on recommendation for the refusal of the marketing authorization for Mycograb. www. emea.europa.eu/humandocs/PDFs/EPAR/mycograb/H-658-RQ&Aen. pdf (accessed 2009 Apr 14).
21. Food and Drug Administration. Cumulative list of all products that have received Orphan Designation. www.fda.gov/orphan/designat/list.htm (accessed 2009 Apr 14).
22. Al-Akeel R, Curry A, Hoyes E, Nooney L, Matthews RC, Burnie JP. Identification of hsp90 in Cryptococcus neoformans and examination of the effect of Mycograb on hsp90 gene expression in cells exposed to various stress factors (abstract P1952). Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy, Munich, Germany, March 3, 2007.
23. National Institutes of Health. Efficacy and safety of Mycograb as adjunctive therapy for cryptococcal meningitis in patients with AIDS. www. clinicaltrials.gov/ct2/show/NCT00847678?term=mycograb&rank=1 (accessed 2009 Jun 2).
24. National Institutes of Health. Preliminary study of Mycograb and docetaxel in advanced breast cancer. www.clinicaltrials.gov/ct2/show/ NCT00217815?term=mycograb&rank=3 (accessed 2009 Jun 2).